TwinBeech Capital
HRMY icon

TwinBeech Capital’s Harmony Biosciences HRMY Stock Holding History

TwinBeech Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,500
Closed -$882K – 518
2026
Q1 		$882K Buy
+31,500
New +$1.03M 0.09% 278
2025
Q4 		– Sell
-33,464
Closed -$922K – 709
2025
Q3 		$922K Buy
+33,464
New +$1.15M 0.04% 323
2024
Q1 		– Sell
-65,421
Closed -$2.11M – 702
2023
Q4 		$2.11M Buy
+65,421
New +$1.83M 0.03% 394
2023
Q2 		– Sell
-14,699
Closed -$480K – 719
2023
Q1 		$480K Buy
+14,699
New +$669K 0.01% 511
2022
Q4 		– Sell
-63,220
Closed -$2.8M – 789
2022
Q3 		$2.8M Buy
+63,220
New +$3.08M 0.07% 292

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's HRMY Position: Q2 2026 in Review

TwinBeech Capital sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 31,500 shares — an estimated $882K sold.

TwinBeech Capital first reported a position in HRMY in Q3 2022 and held it in 5 quarters. The position peaked at $2.8M in Q3 2022. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • TwinBeech Capital reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • TwinBeech Capital sold 31,500 Harmony Biosciences shares in Q2 2026, an estimated $882K.
  • TwinBeech Capital first reported a position in Harmony Biosciences in Q3 2022 and held it in 5 quarters.
  • TwinBeech Capital's Harmony Biosciences position peaked at $2.8M in Q3 2022.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.